272 related articles for article (PubMed ID: 33096752)
1. Toward G-Quadruplex-Based Anticancer Agents: Biophysical and Biological Studies of Novel AS1411 Derivatives.
Ogloblina AM; Iaccarino N; Capasso D; Di Gaetano S; Garzarella EU; Dolinnaya NG; Yakubovskaya MG; Pagano B; Amato J; Randazzo A
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096752
[TBL] [Abstract][Full Text] [Related]
2. Aptamer-based Targeted Delivery of a G-quadruplex Ligand in Cervical Cancer Cells.
Carvalho J; Paiva A; Cabral Campello MP; Paulo A; Mergny JL; Salgado GF; Queiroz JA; Cruz C
Sci Rep; 2019 May; 9(1):7945. PubMed ID: 31138870
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic studies of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation.
Reyes-Reyes EM; Šalipur FR; Shams M; Forsthoefel MK; Bates PJ
Mol Oncol; 2015 Aug; 9(7):1392-405. PubMed ID: 25911416
[TBL] [Abstract][Full Text] [Related]
4. G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms.
Bates PJ; Reyes-Reyes EM; Malik MT; Murphy EM; O'Toole MG; Trent JO
Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt B):1414-1428. PubMed ID: 28007579
[TBL] [Abstract][Full Text] [Related]
5. AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin.
Girvan AC; Teng Y; Casson LK; Thomas SD; Jüliger S; Ball MW; Klein JB; Pierce WM; Barve SS; Bates PJ
Mol Cancer Ther; 2006 Jul; 5(7):1790-9. PubMed ID: 16891465
[TBL] [Abstract][Full Text] [Related]
6. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.
Bates PJ; Laber DA; Miller DM; Thomas SD; Trent JO
Exp Mol Pathol; 2009 Jun; 86(3):151-64. PubMed ID: 19454272
[TBL] [Abstract][Full Text] [Related]
7. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism.
Reyes-Reyes EM; Teng Y; Bates PJ
Cancer Res; 2010 Nov; 70(21):8617-29. PubMed ID: 20861190
[TBL] [Abstract][Full Text] [Related]
8. Bioactivity of 2'-deoxyinosine-incorporated aptamer AS1411.
Fan X; Sun L; Wu Y; Zhang L; Yang Z
Sci Rep; 2016 May; 6():25799. PubMed ID: 27194215
[TBL] [Abstract][Full Text] [Related]
9. Exploring the conformational behaviour and aggregation properties of lipid-conjugated AS1411 aptamers.
Riccardi C; Musumeci D; Russo Krauss I; Piccolo M; Irace C; Paduano L; Montesarchio D
Int J Biol Macromol; 2018 Oct; 118(Pt B):1384-1399. PubMed ID: 30170359
[TBL] [Abstract][Full Text] [Related]
10. Study of the Function of G-Rich Aptamers Selected for Lung Adenocarcinoma.
Hu J; Zhao Z; Liu Q; Ye M; Hu B; Wang J; Tan W
Chem Asian J; 2015 Jul; 10(7):1519-25. PubMed ID: 25864879
[TBL] [Abstract][Full Text] [Related]
11. AS1411 derivatives as carriers of G-quadruplex ligands for cervical cancer cells.
Figueiredo J; Lopes-Nunes J; Carvalho J; Antunes F; Ribeiro M; Campello MPC; Paulo A; Paiva A; Salgado GF; Queiroz JA; Mergny JL; Cruz C
Int J Pharm; 2019 Sep; 568():118511. PubMed ID: 31301466
[TBL] [Abstract][Full Text] [Related]
12. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells.
Soundararajan S; Wang L; Sridharan V; Chen W; Courtenay-Luck N; Jones D; Spicer EK; Fernandes DJ
Mol Pharmacol; 2009 Nov; 76(5):984-91. PubMed ID: 19657047
[TBL] [Abstract][Full Text] [Related]
13. Biophysical and biological properties of quadruplex oligodeoxyribonucleotides.
Dapić V; Abdomerović V; Marrington R; Peberdy J; Rodger A; Trent JO; Bates PJ
Nucleic Acids Res; 2003 Apr; 31(8):2097-107. PubMed ID: 12682360
[TBL] [Abstract][Full Text] [Related]
14. Cell Surface Nucleolin as a Promising Receptor for Effective AS1411 Aptamer-Mediated Targeted Drug Delivery into Cancer Cells.
Mosafer J; Mokhtarzadeh A
Curr Drug Deliv; 2018; 15(9):1323-1329. PubMed ID: 30039760
[TBL] [Abstract][Full Text] [Related]
15. G-rich oligonucleotides for cancer treatment.
Bates PJ; Choi EW; Nayak LV
Methods Mol Biol; 2009; 542():379-92. PubMed ID: 19565914
[TBL] [Abstract][Full Text] [Related]
16. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells.
Soundararajan S; Chen W; Spicer EK; Courtenay-Luck N; Fernandes DJ
Cancer Res; 2008 Apr; 68(7):2358-65. PubMed ID: 18381443
[TBL] [Abstract][Full Text] [Related]
17. Bifunctional G-Quadruplex Aptamer Targeting Nucleolin and Topoisomerase 1: Antiproliferative Activity and Synergistic Effect of Conjugated Drugs.
Jo J; Bae S; Jeon J; Youn H; Lee G; Ban C
Bioconjug Chem; 2023 Jan; 34(1):238-247. PubMed ID: 36516871
[TBL] [Abstract][Full Text] [Related]
18. AS1411-Induced Growth Inhibition of Glioma Cells by Up-Regulation of p53 and Down-Regulation of Bcl-2 and Akt1 via Nucleolin.
Cheng Y; Zhao G; Zhang S; Nigim F; Zhou G; Yu Z; Song Y; Chen Y; Li Y
PLoS One; 2016; 11(12):e0167094. PubMed ID: 27907160
[TBL] [Abstract][Full Text] [Related]
19. Nucleolin Overexpression Confers Increased Sensitivity to the Anti-Nucleolin Aptamer, AS1411.
Sharma VR; Thomas SD; Miller DM; Rezzoug F
Cancer Invest; 2018; 36(9-10):475-491. PubMed ID: 30396283
[TBL] [Abstract][Full Text] [Related]
20. AS1411 Aptamer/Hyaluronic Acid-Bifunctionalized Microemulsion Co-Loading Shikonin and Docetaxel for Enhanced Antiglioma Therapy.
Wang H; Zhu Z; Zhang G; Lin F; Liu Y; Zhang Y; Feng J; Chen W; Meng Q; Chen L
J Pharm Sci; 2019 Nov; 108(11):3684-3694. PubMed ID: 31465736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
